SCM
VRDN icon

Segantii Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Segantii Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-415
Closed -$77K – 254
2017
Q1 		$77K Buy
+415
New +$71.6K 0.01% 228

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Segantii Capital Management's VRDN Position: Q2 2017 in Review

Segantii Capital Management sold out of Viridian Therapeutics (VRDN) in Q2 2017, closing a stake of 415 shares — an estimated $77K sold.

Segantii Capital Management first reported a position in VRDN in Q1 2017 and held it in 1 quarter. The position peaked at $77K in Q1 2017. 31 funds tracked by Wall St. Rank hold VRDN as of Q2 2017.

  • Segantii Capital Management reported no remaining Viridian Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 415 Viridian Therapeutics shares in Q2 2017, an estimated $77K.
  • Segantii Capital Management first reported a position in Viridian Therapeutics in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Viridian Therapeutics position peaked at $77K in Q1 2017.
  • 31 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.